These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 24901365

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC.
    AIDS; 2009 Jul 31; 23(12):1531-8. PubMed ID: 19550287
    [Abstract] [Full Text] [Related]

  • 4. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE, Levy L, Szydlo DW, Zhang J, Gaur AH, Reirden D, Mayer KH, Futterman D, Hoesley C, Hillier SL, Marzinke MA, Hendrix CW, Gorbach PM, Wilson CM, Soto-Torres L, Kapogiannis B, Nel A, Squires KE, MTN-023/IPM 030 Study Team.
    J Acquir Immune Defic Syndr; 2020 Feb 01; 83(2):135-139. PubMed ID: 31929401
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.
    Chen BA, Zhang J, Gundacker HM, Hendrix CW, Hoesley CJ, Salata RA, Dezzutti CS, van der Straten A, Hall WB, Jacobson CE, Johnson S, McGowan I, Nel AM, Soto-Torres L, Marzinke MA, MTN-024/IPM 031 Protocol Team for the Microbicide Trials Network.
    Clin Infect Dis; 2019 Mar 19; 68(7):1144-1151. PubMed ID: 30289485
    [Abstract] [Full Text] [Related]

  • 7. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A, Bekker LG, Bukusi E, Hellstrӧm E, Kotze P, Louw C, Martinson F, Masenga G, Montgomery E, Ndaba N, van der Straten A, van Niekerk N, Woodsong C.
    PLoS One; 2016 Mar 19; 11(3):e0147743. PubMed ID: 26963505
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, Romano J.
    AIDS Res Hum Retroviruses; 2010 Nov 19; 26(11):1181-90. PubMed ID: 20854207
    [Abstract] [Full Text] [Related]

  • 9. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
    Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.
    AIDS; 2016 Mar 13; 30(5):743-51. PubMed ID: 26605514
    [Abstract] [Full Text] [Related]

  • 10. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
    Holt JD, Cameron D, Dias N, Holding J, Muntendam A, Oostebring F, Dreier P, Rohan L, Nuttall J.
    Antimicrob Agents Chemother; 2015 Jul 13; 59(7):3761-70. PubMed ID: 25845860
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.
    Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW.
    J Acquir Immune Defic Syndr; 2010 Oct 13; 55(2):161-9. PubMed ID: 20574411
    [Abstract] [Full Text] [Related]

  • 12. Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.
    Achilles SL, Kelly CW, Hoesley CJ, Blithe DL, Brown J, Richardson BA, Devlin B, Hendrix CW, Poloyac SM, Marzinke MA, Gundacker H, Singh D, Piper JM, Johnson S, Steytler J, Chen BA, MTN-030/IPM 041 and MTN-044/IPM 053/CCN019 Protocol Teams for the Microbicide Trials Network and the Contraceptive Clinical Trials Network.
    PLoS One; 2024 Oct 13; 19(6):e0304552. PubMed ID: 38838028
    [Abstract] [Full Text] [Related]

  • 13. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
    Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S, Mhlanga F, Ramjee G, Mayo AJ, Livant E, Heaps AL, O'Rourke C, Baeten JM, MTN-015 and MTN-020/ASPIRE Study Teams.
    Clin Infect Dis; 2019 Jul 18; 69(3):523-529. PubMed ID: 30346511
    [Abstract] [Full Text] [Related]

  • 14. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
    McBride JW, Malcolm RK, Dias N, Cameron D, Offord RE, Hartley O, Kett VL, Devlin B, Boyd P.
    Int J Pharm; 2019 Jun 10; 564():207-213. PubMed ID: 30999049
    [Abstract] [Full Text] [Related]

  • 15. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
    Robinson JA, Marzinke MA, Bakshi RP, Fuchs EJ, Radebaugh CL, Aung W, Spiegel HM, Coleman JS, Rohan LC, Hendrix CW.
    AIDS Res Hum Retroviruses; 2017 Apr 10; 33(4):339-346. PubMed ID: 27809557
    [Abstract] [Full Text] [Related]

  • 16. Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring.
    McCoy CF, Murphy DJ, Boyd P, Derrick T, Spence P, Devlin B, Malcolm RK.
    J Pharm Sci; 2017 Aug 10; 106(8):2015-2025. PubMed ID: 28456732
    [Abstract] [Full Text] [Related]

  • 17. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
    Reddy K, Kelly C, Brown ER, Jeenarain N, Naidoo L, Siva S, Bekker LG, Nair G, Makanani B, Chinula L, Mgodi N, Chirenje Z, Kiweewa FM, Marrazzo J, Bunge K, Soto-Torres L, Piper J, Baeten JM, Palanee-Phillips T, MTN-020/ASPIRE and MTN-003/VOICE Study Teams.
    AIDS; 2020 Mar 15; 34(4):559-567. PubMed ID: 31764068
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
    Bunge KE, Dezzutti CS, Rohan LC, Hendrix CW, Marzinke MA, Richardson-Harman N, Moncla BJ, Devlin B, Meyn LA, Spiegel HM, Hillier SL.
    J Acquir Immune Defic Syndr; 2016 Apr 15; 71(5):498-505. PubMed ID: 26565716
    [Abstract] [Full Text] [Related]

  • 20. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, Marzinke MA, Bekker LG, Soto-Torres L, Hillier SL, Baeten JM, MTN-020/ASPIRE Study Team.
    J Int AIDS Soc; 2020 Nov 15; 23(11):e25634. PubMed ID: 33206462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.